Mocht u de informatie op kanker-actueel waarderen dan wilt u ons misschien helpen met een donatie? Dat kan op bankrekening:

RABO 37.29.31.138 t.n.v. Stichting Gezondheid Actueel in Terneuzen. 
Onze IBANcode is NL79 RABO 0372 9311 38

17 mei 2019: Lees ook dit artikel: 

https://kanker-actueel.nl/immuuntherapie-met-atezolizumab-plus-avestin-bevacizumab-geeft-betere-progressievrije-ziekte-en-overall-overleving-dan-sunitinib-bij-patienten-met-gevorderde-uitgezaaide-nierkanker.html

4 maart 2019 Lees ook dit artikel: 

https://kanker-actueel.nl/pembrolizumab-plus-axitinib-geeft-betere-overleving-op-1-jaar-plus-11-procent-en-betere-progressievrije-ziekte-dan-met-sunitinib-voor-nog-niet-behandelde-uitgezaaide-nierkanker.html

En lees ook dit artikel: 

https://kanker-actueel.nl/immuuntherapie-met-axitinib-inlyta-en-pembrolizumab-keytruda-bij-gevorderde-nog-onbehandelde-nierkanker-verdubbelt-progressievrije-ziekte-10-vs-20-maanden.html

4 maart 2019. Bron: NEJM februari 2019

Ik plaats dit artikel vanuit een internetcafe in Santo Domingo dus vertaal deze niet want is heel lastig op een oude computer om artikelen te plaatsen, maar wil jullie er wel attent opmaken.

Avelumab plus Axitinib geeft veel betere overall overleving en progressievrije ziekte in vergeljiking emt sunitinib als eerstelijns behandeling bij gevorderde nog neit behandelde nierkanker. Opvallend dat ook de patienten zonder PD-1 ligand mutatie net zoveel profijt ervan hadden dan de patienten met wel een duidelijke PD-1 mutatie. Respectievelijk (13.8 vs 7.2 maanden) en (13,8 vs 8,4 maanden). Onder de patienten met PD-L1–positieve tumoren, was de objectieve respons hoger voor avelumab plus axitinib (55.2%) vergeleken met avelumab plus sunitinib (25.5%)

Dit zijn de resultaten uit deze studie:

  • In this phase Ib study, 886 patients were randomized to receive avelumab plus axitinib or sunitinib to investigate survival outcomes. In patients with PD-L1–positive tumors (n = 560), the median progression-free survival was significantly prolonged in patients receiving avelumab plus axitinib compared with patients receiving avelumab plus sunitinib (13.8 vs 7.2 months). Similar results were reported in the overall population (13.8 vs 8.4 months). Among patients with PD-L1–positive tumors, the objective response rate was higher in patients receiving avelumab plus axitinib (55.2%) compared with those receiving avelumab plus sunitinib (25.5%). A similar proportion of adverse events was reported in both groups.
  • The first-line combination of avelumab plus axitinib led to significantly prolonged progression-free survival compared with avelumab plus sunitinib in patients with advanced RCC.

Het studierapport: Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma is tegen betaling in te zien.

Hier het abstract van de studie:

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

  • Robert J. Motzer, M.D., 
  • Konstantin Penkov, M.D., Ph.D., 
  • John Haanen, Ph.D., 
  • Brian Rini, M.D., 
  • Laurence Albiges, M.D., Ph.D., 
  • Matthew T. Campbell, M.D., 
  • Balaji Venugopal, M.D., 
  • Christian Kollmannsberger, M.D., 
  • Sylvie Negrier, M.D., Ph.D., 
  • Motohide Uemura, M.D., Ph.D., 
  • Jae L. Lee, M.D., Ph.D., 
  • Aleksandr Vasiliev, M.D., 

Abstract

BACKGROUND

In a single-group, phase 1b trial, avelumab plus axitinib resulted in objective responses in patients with advanced renal-cell carcinoma. This phase 3 trial involving previously untreated patients with advanced renal-cell carcinoma compared avelumab plus axitinib with the standard-of-care sunitinib.

METHODS

We randomly assigned patients in a 1:1 ratio to receive avelumab (10 mg per kilogram of body weight) intravenously every 2 weeks plus axitinib (5 mg) orally twice daily or sunitinib (50 mg) orally once daily for 4 weeks (6-week cycle). The two independent primary end points were progression-free survival and overall survival among patients with programmed death ligand 1 (PD-L1)–positive tumors. A key secondary end point was progression-free survival in the overall population; other end points included objective response and safety.

RESULTS

A total of 886 patients were assigned to receive avelumab plus axitinib (442 patients) or sunitinib (444 patients). Among the 560 patients with PD-L1–positive tumors (63.2%), the median progression-free survival was 13.8 months with avelumab plus axitinib, as compared with 7.2 months with sunitinib (hazard ratio for disease progression or death, 0.61; 95% confidence interval , 0.47 to 0.79; P<0.001); in the overall population, the median progression-free survival was 13.8 months, as compared with 8.4 months (hazard ratio, 0.69; 95% CI, 0.56 to 0.84; P<0.001). Among the patients with PD-L1–positive tumors, the objective response rate was 55.2% with avelumab plus axitinib and 25.5% with sunitinib; at a median follow-up for overall survival of 11.6 months and 10.7 months in the two groups, 37 patients and 44 patients had died, respectively. Adverse events during treatment occurred in 99.5% of patients in the avelumab-plus-axitinib group and in 99.3% of patients in the sunitinib group; these events were grade 3 or higher in 71.2% and 71.5% of the patients in the respective groups.

CONCLUSIONS

Progression-free survival was significantly longer with avelumab plus axitinib than with sunitinib among patients who received these agents as first-line treatment for advanced renal-cell carcinoma. (Funded by Pfizer and Merck [Darmstadt, Germany]; JAVELIN Renal 101 ClinicalTrials.gov number, NCT02684006.)


Plaats een reactie ...

Reageer op "Avelumab plus Axitinib geeft veel betere progressievrije overleving (plus 5 maanden) dan sunitinib als eerstelijns behandeling bij nog niet behandelde uitgezaaide nierkanker."


Gerelateerde artikelen
 

Gerelateerde artikelen

Immuuntherapie met Atezolizumab >> Avelumab plus Axitinib geeft >> Pembrolizumab plus Axitinib >> immuuntherapie met axitinib >> Immuuntherapie met rocapuldencel-T >> Belangrijke abstracten van >> HIFU - High Focused Ultra >> Interferon Alpha als aanvullende >> Nexavar(R) (sorafenib tosylate) >> Nivolumab (Obvio) alleen en >>